mAbxience | Our story: moving forward

Our story:
moving forward

  • 2019

    • New partnerships in EU, Russia, Japan and other key markets
    • Australian GMP certification granted to mAbxience León
    • New state-of-the-art mAbxience facility opening in Bs As

  • 2018

    • Alliances with leading pharma companies in EE, USA, and Australia
    • Turkish GMP certification grantes to mAbxience León
    • First rituximab launch in the Jordan market
    • Business Development of the Year Award 2018 by GGBA

  • 2017

    • European GMP certification granted to mAbxience León
    • Initiation of project for the construction of a new mAb facility in Bs As
    • Scientific Advices with the EMA and the FDA
    • Clinical trials of rituximab and bevacizumab completed
    • Expasion of global acces of rituximab

  • 2016

    • Bevax® (bevacizumab) launch in Argentina
    • Project with WHO and UCAB to develop Palivizumab biosimilar
    • Biosimilar Initiative of the Year Award 2016 by GGBA

  • 2015

    • mAbxience León plant: inauguration

  • 2014

    • Genhelix biopharmaceutical plant acquisition (León, Spain)
    • Novex® (rituximab) launch in Argentina

  • 2013

    • Clinical trial recruitment (bevacizumab)

  • 2012

    • mAbxience Buenos Aires plant: inauguration
    • ANMAT GMP certification to mAbxience Bs As
    • First industrial batch
    • First clinical trial recruitment (rituximab)

  • 2010

    • Acquisition and start of construction of pharmADN (mAbxience Bs As facility)

  • 2009

    • Established in Europe
    • Start of R&D activities

ANMAT: National Administration of Drugs, Foods and Medical Devices.

WHO: World Health Organization.

UCAB: Utrecht Centre for Affordable Biotherapeutics.

GMP: Good Manufacturing Practices.

AEMPS: Spanish Agency for Medicines and Medical Devices

EMA: European Medicines Agency

FDA: US Food Drug Administration

TGA: Australia Therapeutic Goods Administration

GGBA: Global Generics & Biosimilar Awards